Clinical Trials
43 trialsNCT07054190 2026-05-26
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT06979596 2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04553133 2026-05-06
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05226871 2025-11-25
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
Phase 2 Active not recruiting
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT06465368 2025-10-01
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
Pfizer
Phase 2 Completed
NCT04191382 2025-09-18
AMEERA-4
Sanofi
Phase 2 Terminated
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT01698918 2023-05-03
BOLERO-4
Novartis
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT00880009 2021-09-27
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
Pfizer
Phase 2 Terminated
NCT01231659 2021-03-26
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT01684215 2020-11-23
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT00796107 2020-11-13
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01225172 2020-08-11
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Bristol-Myers Squibb
Phase 2 Terminated
NCT00721409 2019-11-04
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT00237211 2018-11-14
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Novartis
Phase 2 Completed
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02273973 2018-05-21
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Genentech, Inc.
Phase 2 Completed
NCT00247650 2017-03-01
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
Novartis
Phase 2 Completed
NCT00237198 2017-02-23
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
Novartis
Phase 2 Completed
NCT00171808 2016-11-18
deFEND
Novartis
Phase 2 Completed
NCT00696072 2016-06-13
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Bristol-Myers Squibb
Phase 2 Completed
NCT00422903 2016-05-12
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01919229 2016-01-01
MONALEESA-1
Novartis
Phase 2 Terminated
NCT01068704 2015-10-12
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT01430585 2014-08-12
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
Pfizer
Phase 2 Terminated
NCT00708214 2013-12-30
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00107016 2013-03-04
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
Novartis
Phase 2 Completed
NCT00247663 2012-04-19
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Novartis
Phase 2 Completed
NCT00333086 2012-04-19
A Study of Letrozole in the Treatment of Endometrial Cancer
Novartis
Phase 2 Completed
NCT00062751 2011-04-15
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00770354 2009-08-10
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
Antisoma Research
Phase 2 Terminated